Collateral for a security interest recorded Dec 10, 2021 (JPMorgan Chase Bank, N.A.).
Term ends no later than May 18, 2032 · Medium confidence
20-year base term ends May 18, 2032
In force on USPTO's status record and by its fee record. A terminal disclaimer on file may shorten this term, possibly to a date already past; its reference document is unresolved, so the date above is an upper bound and no earlier date is guessed.
Held by Agena Bioscience, Inc.
Filed Jul 17, 2012 as application 13/551,486 · Granted Mar 31, 2020
Base term, 20 years from filing
Today
2012
2032
Clock starts
May 18, 2012
May 18, 2012
Ends no later than
May 18, 2032
May 18, 2032
Granted
Mar 31, 2020
Mar 31, 2020
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
Unresolved
Terminal disclaimer
On file, reference document not resolved, so the date above is an upper bound. We do not guess the cap.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. 1 of 3 maintenance fees is paid so far. Confidence: Medium. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts May 18, 2012, when application PCT/US2012/038710, the earliest non-provisional in its chain, was filed (this one was filed Jul 17, 2012) | May 18, 2032 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | no later than May 18, 2032 | Medium confidence |
This family
| Application PCT/US2012/038710 | PCT application no patent term | no patent term |
| US 10,604,791 | this patent no later than May 2032 | no later than May 2032 |
| Application 13/790,996 | Abandoned not computed | not computed |
| US 11,667,958 | In force May 2032 | May 2032 |
| US 12,630,865 | In force May 2032 | May 2032 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 17, 2012 Reel 29484, frame 536 | Honisch, Christiane; Van Den Boom, Dirk Johannes; Mosko, Michael; Nygren, Anders | Sequenom, Inc. | Assignment of Assignor's Interest |
| Jun 16, 2014 Reel 33182, frame 62 | Sequenom, Inc. | Biosciences Acquisition Company | Assignment of Assignor's Interest |
| Jun 27, 2014 Reel 33248, frame 73 | Biosciences Acquisition Company | Agena Bioscience, Inc. | Change of Name |
| Feb 3, 2017 Reel 41621, frame 548 | Agena Bioscience, Inc. | Midcap Financial Trust | Security Interest |
| Mar 21, 2017 Reel 42050, frame 888 | Agena Bioscience, Inc. | Midcap Financial Trust, As Agent | Security Interest |
| Jul 13, 2021 Reel 56860, frame 557 | Midcap Financial Trust | Agena Bioscience, Inc. | Release of Security Interest in Reel 041621 Frame 0548 |
| Dec 7, 2021 Reel 58741, frame 5 | Midcap Funding IV Trust | Agena Bioscience, Inc. | Release of Security Interest |
| Dec 10, 2021 Reel 58358, frame 661 | Agena Bioscience, Inc. | Jpmorgan Chase Bank, N.a. | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
May 2032
Term ends no later than May 18, 2032. Maintenance fees still fall due before then
Note
A terminal disclaimer is on file and its reference is not resolved. No cap is applied and none is guessed
Open question
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than May 18, 2032. We will not guess the cap.
Citations
16
later US patents cite this one
That is top 25% of utility patents granted in 2020 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
This computed term ends no later than the date shown; an unresolved terminal disclaimer may end it earlier. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.